National Healthcare set its Nasdaq listing for April 22, pricing 38.5 million shares at $12 each and raising approximately $462 million in gross proceeds. The offering lands in the narrow window between first-quarter earnings blackouts and Memorial Day, when institutional desks typically lighten allocations ahead of summer.

The company priced at the midpoint of its filing range, avoiding the discounts that marked February's healthcare IPOs. Underwriters have not disclosed the greenshoe size, though standard practice would add 5.775 million shares of potential upside if demand holds past the first five trading days. National Healthcare joins a Nasdaq healthcare cohort that has seen 14 listings year-to-date, seven of which now trade below their offer prices.

The timing matters for two reasons. First, the April 22 debut falls three weeks after the Russell reconstitution preliminary list publishes, meaning National Healthcare misses the June rebalance and will not see passive inflows until 2026. Second, the $462 million raise positions the company at the lower end of meaningful institutional scale—large enough for mid-cap funds but small enough that three anchor orders could move the book. Healthcare allocators have been disciplined this year, requiring visible paths to EBITDA expansion rather than revenue multiples alone.

What separates this deal from the crowded med-tech pipeline is the absence of venture backing in the cap table. National Healthcare appears to be a rollup or established operator accessing public markets for M&A currency, not a growth-stage company burning toward profitability. That structure appeals to a different buyer—family offices and insurance allocators who want yield visibility and manageable volatility, not venture crossover funds hunting for doubles.

Allocators should track first-day volume relative to the 38.5 million float. If turnover exceeds 60% in the first session, flippers dominate the book and the stock will likely drift. If volume holds below 40%, institutional anchors are present and the name may find support. The lockup period—typically 180 days—will expire in mid-October, ahead of year-end tax-loss selling, so any insider distribution will compress into a narrow November window.

National Healthcare's debut will clarify whether non-tech healthcare can still command full pricing in a market that has rewarded only AI infrastructure and weight-loss pharmacology over the past eight months.